ArticleNeurosurgery2026
Plasma Proteomic Biomarkers of Degenerative Cervical Myelopathy in the UK Biobank.
Article in Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe diagnosis of spinal cord dysfunction in degenerative cervical myelopathy (DCM) is currently based on correlating clinical signs and symptoms with neuroimaging findings. Plasma proteomics represents an opportunity to establish objective, blood-based biomarkers, which predict DCM severity or response to surgical intervention. These methods may also support novel insights into its pathophysiological relationship with other neurological diseases, such as multiple sclerosis (MS), which also can present with myelopathy, or peripheral neuropathy (PN), which has overlapping symptoms with DCM. In this study, we examined the relationships between circulating blood protein levels with DCM, MS, and PN using data from the UK Biobank Pharma Proteomics Project.
methodsThe plasma proteomic profiles of participants with a diagnosis of DCM within 5 years of blood draw, who had not undergone surgical intervention (n = 42) were compared with those without known neural injury or neurodegenerative disease (n = 39 519) using case-control matching. To further characterize the difference between central and peripheral nerve injury, case-control analyses were also performed using participants with a diagnosis of MS (n = 125) and PN (n = 101) within 5 years of blood draw.
resultsThe top proteins significantly associated with DCM included neuron markers RNA-binding Fox-1 homolog 3 and neurofilament light chain. These proteins were also significantly elevated in the PN group relative to controls, and neurofilament light was elevated in MS.
conclusionThese findings suggest that neural injury in DCM can be detected using blood protein levels and may hold value in diagnostic, monitoring, and potentially prognostic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.